The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031
Open accessAbstract
We previously reported preliminary findings that post induction imatinib mesylate (340 mg/m2/day), in combination with intensive chemotherapy, resulted in outcomes similar to blood and marrow transplant (BMT) for pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We now report 5-year outcomes of imatinib plus intensive chemotherapy in 91 children (1–21 years) with and without allogeneic BMT (N=91). We explore the impacts of additional chromosomal abnormalities and minimal residual disease (MRD) by flow cytometry on outcomes. The 5-year disease-free survival was similar for Cohort 5 patients, treated with chemotherapy plus imatinib (70%±12%, n=28), sibling donor BMT patients (65%±11%, n=21) and unrelated donor BMT patients (59±15%; P=0.60, n=13). Patients with additional cytogenetic abnormalities had worse outcomes (P=0.05). End induction (pre-imatinib) MRD was not prognostic for Cohort 5 or allogeneic BMT patients, although limited by small numbers. The re-induction rate following relapse was similar to other higher-risk ALL groups. Longer-term follow-up confirms our initial observation of substantially good outcomes for children and adolescents with Ph+ ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Treatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S., Martin, P. L., Pullen, D. J., Viswanatha, D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 842
Self-citationSchultz, K. R., Bowman, W. P., Aledo, A., Slayton, W. B., Sather, H., Devidas, M., Wang, C., Davies, S. M., Gaynon, P. S., Trigg, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2514 · Cited by 701
Self-citationOutcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Aricò, M., Valsecchi, M. G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., Gaynon, P., Silverman, L., Janka-Schaub, G., Kamps, W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004063421402 · Cited by 600
Self-citationBader, P., Kreyenberg, H., Henze, G. H. R., Eckert, C., Reising, M., Willasch, A., Barth, A., Borkhardt, A., Peters, C., Handgretinger, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.6065 · Cited by 357
Biondi, A., Schrappe, M., De Lorenzo, P., Castor, A., Lucchini, G., Gandemer, V., Pieters, R., Stary, J., Escherich, G., Campbell, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70377-7 · Cited by 330
Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995
Gaynon, P., Trigg, M., Heerema, N., Sensel, M., Sather, H., Hammond, G., & Bleyer, W. (2000) · Leukemia · doi:10.1038/sj.leu.2401939 · Cited by 319
Self-citation
Cited by
Acute Lymphoblastic Leukemia in Children
Hunger, S. P., & Mullighan, C. G. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1400972 · Cited by 2,204
Self-citationChildhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Pui, C.-H., Yang, J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A., Vora, A., Baruchel, A., Silverman, L. B., Schmiegelow, K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1636 · Cited by 1,007
Self-citationMalard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
Pediatric acute lymphoblastic leukemia
Inaba, H., & Mullighan, C. G. (2020) · Haematologica · doi:10.3324/haematol.2020.247031 · Cited by 696
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
Chalandon, Y., Thomas, X., Hayette, S., Cayuela, J.-M., Abbal, C., Huguet, F., Raffoux, E., Leguay, T., Rousselot, P., Lepretre, S., et al. (2015) · Blood · doi:10.1182/blood-2015-02-627935 · Cited by 379
Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia
Liu, Y.-F., Wang, B.-Y., Zhang, W.-N., Huang, J.-Y., Li, B.-S., Zhang, M., Jiang, L., Li, J.-F., Wang, M.-J., Dai, Y.-J., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.038 · Cited by 333
Biology of Childhood Acute Lymphoblastic Leukemia
Bhojwani, D., Yang, J. J., & Pui, C.-H. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.004 · Cited by 311
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group
Reshmi, S. C., Harvey, R. C., Roberts, K. G., Stonerock, E., Smith, A., Jenkins, H., Chen, I.-M., Valentine, M., Liu, Y., Li, Y., et al. (2017) · Blood · doi:10.1182/blood-2016-12-758979 · Cited by 302
Self-citationPhiladelphia chromosome–like acute lymphoblastic leukemia
Tasian, S. K., Loh, M. L., & Hunger, S. P. (2017) · Blood · doi:10.1182/blood-2017-06-743252 · Cited by 296
Self-citationComparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
Teachey, D. T., & Pui, C.-H. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30031-2 · Cited by 291
Möricke, A., Zimmermann, M., Valsecchi, M. G., Stanulla, M., Biondi, A., Mann, G., Locatelli, F., Cazzaniga, G., Niggli, F., Aricò, M., et al. (2016) · Blood · doi:10.1182/blood-2015-09-670729 · Cited by 283
Jabbour, E., Short, N. J., Ravandi, F., Huang, X., Daver, N., DiNardo, C. D., Konopleva, M., Pemmaraju, N., Wierda, W., Garcia-Manero, G., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30176-5 · Cited by 273
Adolescent and young adult patients with cancer: a milieu of unique features
Sender, L., & Zabokrtsky, K. B. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.92 · Cited by 130
Metadata
- Authors
- Schultz, K. R., Carroll, A., Heerema, N. A., Bowman, W. P., Aledo, A., Slayton, W. B., Sather, H., Devidas, M., Zheng, H. W., Davies, S. M., Gaynon, P. S., Trigg, M., Rutledge, R., Jorstad, D., Winick, N., Borowitz, M. J., Hunger, S. P., Carroll, W. L., Camitta, B., & from the Children’s Oncology Group
- Venue
- Leukemia
- Published
- 2014-01-20
- Volume
- 28
- Issue
- 7
- Pages
- 1467-1471
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2047597898
- Cited by
- 447
- References
- 18
- FWCI
- 43.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.